Carisma Therapeutics Inc (Nasdaq: CARM), a US-based clinical-stage biopharmaceutical company, announced on Tuesday that it has added Dr Scott Friedman and Dr Ira Tabas to its Scientific Advisory Board (SAB).

Dr Friedman serves as the chief emeritus of Liver Diseases at the Icahn School of Medicine at Mount Sinai. He has also served as president of the American Association for the Study of Liver Diseases (AASLD) and is a fellow of the American Association for the Advancement of Science. He currently consults for around 25 companies in the liver disease space.

Dr Tabas serves as the Richard J. Stock professor and vice-chair of Research in the Department of Medicine and Professor of Pathology and Cell Biology (in Physiology and Cellular Biophysics) at Columbia University in New York City. He has also worked on the board of Reviewing Editors for the journal Science and has been elected to both the Society for Clinical Investigation and the Association of American Physicians.